Citation Information :
Prakash A, Sourabh S, Rudra PN, Kumar S, Abraham SE. Metabolic Syndrome in Patients with Depression: A Cross-sectional Comparative Study. Ind J Priv Psychiatry 2023; 17 (1):34-39.
Background: Depression is a leading cause of disability worldwide and is also known to be comorbid with a number of medical and psychiatric illnesses. Metabolic syndrome (MS) that is now emerging as a common lifestyle illness is found to be twofold greater in patients with depression. Often, antidepressants have been considered to be the reason for this possible link, however, research from the West suggests that a direct link is plausible. There is a scarcity of literature supporting these data from the East. In this study, we have attempted to assess the prevalence of MS in depressive patients, and to determine the probable risk factors contributing to the association.
Materials and methods: Sixty consecutive patients that fulfilled the inclusion criteria were recruited from a tertiary care center in India. Sociodemographic and clinical data were obtained using a semistructured pro forma. Depressive disorder was diagnosed using International classification of diseases-10 (ICD-10), and severity was measured using Hamilton rating scale for depression (HAM-D). The weight, height, waist circumference (WC), systolic and diastolic blood pressure (BP), as well as fasting lipids and glucose were measured. Metabolic syndrome was diagnosed based on National Cholesterol Education Program/Adult Treatment Panel (NCEP ATP-III) criteria (2005 revision). The descriptive and inferential statistics were done using statistical package for social sciences (SPSS) 16.
Results and conclusion: The overall prevalence of MS among depressed patients was 35%. The prevalence among “drug-naive” patients was 30%, whereas among “on-drug” patients was 40%. The most common abnormal MS components were WC (53.33%), systolic BP (SBP) (53.3%), and high-density lipoprotein (HDL) (53.3%). Age of the patient was the only sociodemographic factor that showed significant correlation with components of MS like fasting blood sugar (FBS) and SBP. Age of onset of depression among MS cases had a negative correlation with WC. Among the MS components, the distribution of diastolic BP (DBP) and triglycerides (TG) was statistically different among the “drug-naive” and “on-drug” groups. Thus, in view of significant number of depressed patients being at risk of developing MS, it would be necessary to keep a regular check on metabolic parameters in this group of patients.
Sadock BJ, Sadock VA. Depression and Bipolar disorder. In: Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Lippincott Williams and Wilkins: Philadelphia; 2007. pp. 529–530.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392 (10159):1789–1858. DOI: 10.1016/S0140-6736 (18) 32279-7.
Eckel RH. The metabolic syndrome. In: Harrison's Principles of Internal Medicine. 18th ed. The McGraw Hill Companies; 2012.
Pan A, Keum N, Okereke OI, et al. Bidirectional association between depression and metabolic syndrome: A systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012;35(5):1171–1180. DOI: 10.2337/dc11-2055.
Gil K, Radziłłowicz P, Zdrojewski T, et al. Relationship between the prevalence of depressive symptoms and metabolic syndrome. Results of the SOPKARD Project. Kardiol Pol 2006;64(5):464–469. PMID: 16752328.
Chokka P, Tancer M, Yeragani VK. Metabolic syndrome: Relevance to antidepressant treatment. J Psychiatry Neurosci 2006;31(6):414. PMID: 17136222.
Toalson P, Ahmed S, Hardy T, et al. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 2004;6(4):152–158. DOI: 10.4088/pcc.v06n0402.
Heiskanen TH, Niskanen LK, Hintikka JJ, et al. Metabolic syndrome and depression: A cross-sectional analysis. J Clin Psychiatry 2006;67(9):1422–1427. DOI: 10.4088/jcp.v67n0913.
Richter N, Juckel G, Assion H-J. Metabolic syndrome: A follow-up study of acute depressive inpatients. Eur Arch Psychiatry Clin Neurosci 2010;260(1):41–49. DOI: 10.1007/s00406-009-0013-5.
John AP, Koloth R, Dragovic M, et al. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009;190(4):176–179. DOI: 10.5694/j.1326-5377.2009.tb02342.x.
Teixeira PJR, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psychiatry 2007;29(4):330–336. DOI: 10.1590/s1516-44462007000400007.
Grover S, Nebhinani N, Chakrabarti S, et al. Metabolic syndrome in drug-naïve patients with depressive disorders. Indian J Psychol Med 2013;35(2):167–173. DOI: 10.4103/0253-7176.116247.
Agarwal A, Agarwal M, Garg K, et al. Metabolic syndrome and central obesity in depression: A cross-sectional study. Indian J Psychiatry 2016;58(3):281–286. DOI: 10.4103/0019-5545.192021.
Pyykkönen A-J, Räikkönen K, Tuomi T, et al. Stressful life events and the metabolic syndrome: The prevalence, prediction and prevention of diabetes (PPP) – Botnia study. Diabetes Care 2010;33(2):378–384. DOI: 10.2337/dc09-1027.
East C, Willis BL, Barlow CE, et al. Depressive symptoms and metabolic syndrome in preventive healthcare: The Cooper Center longitudinal study. Metab Syndr Relat Disord 2010;8(5):451–457. DOI: 10.1089/met.2010.0017.
Demirici H, Cinar Y, Bilgel N. Metabolic syndrome and depressive symptoms in a primary health care setting in Turkey. Klinik Psikofarmakoloji Bulteni 2011;21(1):49–57. DOI: 10.5350/KPB-BCP201121108.
Kinder LS, Carnethon MR, Palaniappan LP, et al. Depression and the metabolic syndrome in young adults: Findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004;66(3):316–322. DOI: 10.1097/01.psy.0000124755.91880.f4.